Featured
-
-
Outlook |
Innovative cancer therapies offer new hope
The arsenal of weapons used to treat these insidious diseases is rapidly expanding.
- Herb Brody
-
Outlook |
Advances in highly targeted radiation treatment for cancer have ignited interest in a once obscure field
Therapies that treat while diagnosing — theranostics — can extend length of survival and improve the quality of life for some people with advance-stage cancer.
- Rachel Nuwer
-
Outlook |
Randomized trials of cancer drugs are for yesterday
Pitting new treatments against old, ineffective agents is neither ethical nor economical.
- Elaine Schattner
-
Outlook |
How antibody–drug conjugates aim to take down cancer
Scientists are trying to work out how to balance potency with toxicity and tackle the cost of next-generation therapeutics.
- Benjamin Plackett
-
Outlook |
Turning tumours against themselves
Advances in in situ therapeutic cancer vaccines offer a mode of treatment that could redeem the promise of previous false dawns.
- Liam Drew
-
Outlook |
AI assistance for planning cancer treatment
Armed with the right data, advances in machine learning could help oncologists to home in quickly on the best treatment strategies for their patients.
- Michael Eisenstein
-
Outlook |
Natural killer cells show their cancer-fighting worth
Although natural-killer-cell therapies are safer than T-cell therapies and offer other advantages, they require upgrades to overcome their limited lifespan and susceptibility to immunosuppression.
- Amanda B. Keener
-
Article
| Open AccessSelective haematological cancer eradication with preserved haematopoiesis
An antibody–drug conjugate that targets the pan-haematopoietic marker CD45 combined with transplanted stem cells engineered to be shielded from it can eradicate leukaemic cells while preserving haematopoiesis.
- Simon Garaudé
- , Romina Marone
- & Lukas T. Jeker
-
Article |
Covalent targeted radioligands potentiate radionuclide therapy
Radiopharmaceuticals engineered with click chemistry to selectively bind to tumour-specific proteins can be used to successfully target tumour cells, boosting the pharmacokinetics of radionuclide therapy and improving tumour regression.
- Xi-Yang Cui
- , Zhu Li
- & Zhibo Liu
-
Article
| Open AccessA whole-slide foundation model for digital pathology from real-world data
Prov-GigaPath, a whole-slide pathology foundation model pretrained on a large dataset containing around 1.3 billion pathology images, attains state-of-the-art performance in cancer classification and pathomics tasks.
- Hanwen Xu
- , Naoto Usuyama
- & Hoifung Poon
-
News |
Gut microbes linked to fatty diet drive tumour growth
Scientists know there is a link between obesity and some cancers. A study in mice and people suggests why that might be.
- Gillian Dohrn
-
Review Article |
Decoding the interplay between genetic and non-genetic drivers of metastasis
This Review discusses the importance of genetic and non-genetic reprogramming events during the metastatic cascade.
- Panagiotis Karras
- , James R. M. Black
- & Jean-Christophe Marine
-
Article
| Open AccessEngineered CD47 protects T cells for enhanced antitumour immunity
Combination of TCR or CAR T cells expressing the engineered CD47 variant 47E with anti-CD47 antibody therapy results in synergistic antitumour efficacy due to T cell resistance to clearance by macrophages, while maintaining macrophage recruitment into the tumour microenvironment.
- Sean A. Yamada-Hunter
- , Johanna Theruvath
- & Crystal L. Mackall
-
Article |
Mapping genotypes to chromatin accessibility profiles in single cells
The JAK2V617F mutation leads to epigenetic rewiring in a cell-intrinsic and cell-type-specific manner, influencing inflammation states and differentiation trajectories in patients with myeloproliferative neoplasms.
- Franco Izzo
- , Robert M. Myers
- & Dan A. Landau
-
Article |
Targetable leukaemia dependency on noncanonical PI3Kγ signalling
Using a multimodal approach across acute leukaemias, a targetable PI3Kγ dependency in leukaemias is explored.
- Qingyu Luo
- , Evangeline G. Raulston
- & Andrew A. Lane
-
News & Views |
Genomics reveal unknown mutation-promoting agents at global sites
Genetic sequencing of human kidney cancers worldwide has revealed associations between geographical locations and specific mutation patterns, indicating exposure to known and unknown mutation-promoting agents.
- Irene Franco
- & Fran Supek
-
Nature Podcast |
Dad’s microbiome can affect offspring’s health — in mice
Disrupting gut microbes increases risk of growth issues in the next generation, and understanding geographic variations in cancer rates.
- Benjamin Thompson
- & Nick Petrić Howe
-
Article
| Open AccessGeographic variation of mutagenic exposures in kidney cancer genomes
Whole-genome sequencing of 962 clear cell renal cell carcinomas from 11 countries shows geographic variations in somatic mutation profiles, including a mutational signature of unknown cause in 70% of cases from Japan.
- Sergey Senkin
- , Sarah Moody
- & Paul Brennan
-
Article |
3D genomic mapping reveals multifocality of human pancreatic precancers
Quantitative multimodal 3D reconstruction of human pancreatic tissue at single-cell resolution reveals a high burden of multifocal, genetically heterogeneous pancreatic intraepithelial neoplasias in the normal adult pancreas.
- Alicia M. Braxton
- , Ashley L. Kiemen
- & Laura D. Wood
-
News Feature |
Do cutting-edge CAR-T-cell therapies cause cancer? What the data say
Regulators have identified around 30 cases of cancer linked to this blockbuster treatment. But is CAR T to blame? The hunt is on for answers.
- Cassandra Willyard
-
News & Views |
Bioengineered ‘mini-colons’ shed light on cancer progression
Cells grown on a 3D scaffold have generated a ‘mini-colon’ that mimics key features of the organ. Controlled expression of cancer-associated genes in the system offers a way to examine tumour formation over space and time.
- Nicolò Riggi
- & Felipe de Sousa e Melo
-
News & Views |
Tumours form without genetic mutations
Researchers find that brief and reversible inhibition of a gene-silencing mechanism leads to irreversible tumour formation in fruit flies, challenging the idea that cancer is caused only by permanent changes to DNA.
- Anne-Kathrin Classen
-
News |
Mini-colon and brain ‘organoids’ shed light on cancer and other diseases
Tiny 3D structures made from human stem cells sometimes offer insights that animal models cannot.
- Sara Reardon
-
Article
| Open AccessDiscovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers
HRO761 is a potent, selective, allosteric WRN inhibitor that binds at the interface of the D1 and D2 helicase domains, locking WRN in an inactive conformation.
- Stephane Ferretti
- , Jacques Hamon
- & Marta Cortés-Cros
-
Article
| Open AccessSpatiotemporally resolved colorectal oncogenesis in mini-colons ex vivo
Topobiologically complex mini-colons—which enable the faithful in vitro recapitulation of colorectal cancer tumorigenesis and its environmental determinants—offer the possibility to reduce animal use in a wide range of experimental applications.
- L. Francisco Lorenzo-Martín
- , Tania Hübscher
- & Matthias P. Lutolf
-
Article
| Open AccessPGE2 inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function
Prostaglandin E2 from the tumour microenvironment impairs interleukin-2 sensing by tumour-infiltrating lymphocytes, restricting proliferative response and promoting T cell death via metabolic impairment and ferroptosis.
- Matteo Morotti
- , Alizee J. Grimm
- & George Coukos
-
Article
| Open AccessPGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells
Tumour-derived prostaglandin E2, signaling through its receptors EP2 and EP4, is shown to restrain the responses of tumour-infiltrating stem-like TCF1+CD8+ T lymphocytes, and modulation of T cell EP2 and EP4 can restore anticancer immunity.
- Sebastian B. Lacher
- , Janina Dörr
- & Jan P. Böttcher
-
Article |
Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase
VVD-133214, a clinical-stage, covalent allosteric inhibitor of the helicase WRN, was well tolerated in mice and led to robust tumour regression in multiple microsatellite-instability-high colorectal cancer cell lines and patient-derived xenograft models.
- Kristen A. Baltgalvis
- , Kelsey N. Lamb
- & Todd M. Kinsella
-
News |
AI traces mysterious metastatic cancers to their source
Algorithm examines images of metastatic cells to identify the location of the primary tumour.
- Smriti Mallapaty
-
Research Highlight |
Biological age surges in survivors of childhood cancer
People who survived paediatric cancers age faster and are at higher risk of early death.
-
News |
How to supercharge cancer-fighting cells: give them stem-cell skills
The bioengineered immune players called CAR T cells last longer and work better if pumped up with a large dose of a protein that makes them resemble stem cells.
- Sara Reardon
-
Article
| Open AccessFOXO1 is a master regulator of memory programming in CAR T cells
The transcription factor FOXO1 has a key role in human T cell memory, and manipulating FOXO1 expression could provide a way to enhance CAR T cell therapies by increasing CAR T cell persistence and antitumour activity.
- Alexander E. Doan
- , Katherine P. Mueller
- & Evan W. Weber
-
Article
| Open AccessThe PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
A study details the results of the PARTNER trial, a prospective, randomized controlled trial of the use of neoadjuvant olaparib with carboplatin–paclitaxel chemotherapy in patients with triple-negative breast cancer who were germline BRCA1 and BRCA2 wild type.
- Jean E. Abraham
- , Karen Pinilla
- & Helena M. Earl
-
Article
| Open AccessConcurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
RMC-7977, a compound that exhibits potent inhibition of the active states of mutant and wild-type KRAS, NRAS and HRAS variants has a strong anti-tumour effect on RAS-addicted tumours and is well tolerated in preclinical models.
- Matthew Holderfield
- , Bianca J. Lee
- & Mallika Singh
-
Article
| Open AccessTumour-selective activity of RAS-GTP inhibition in pancreatic cancer
RMC-7977, a multi-selective RAS(ON) inhibitor, exhibits potent tumour-selective activity in multiple pre-clinical models of pancreatic ductal adenocarcinoma through a combination of pharmacology and oncogene dependence.
- Urszula N. Wasko
- , Jingjing Jiang
- & Kenneth P. Olive
-
Nature Podcast |
Audio long read: Why are so many young people getting cancer? What the data say
Researchers are scrambling to explain why rates of multiple cancers are increasing among adults under the age of 50.
- Heidi Ledford
- & Benjamin Thompson
-
Outline |
Video: Cancer-busting vaccines
Treatments that could train the immune system to identify and destroy cancer cells are on the way.
-
Outline |
Cancer-vaccine trials give reasons for optimism
Therapeutic vaccines could provide a transformative shot in the arm for cancer treatment.
- Liam Drew
-
Outline |
How does a cancer vaccine work?
After decades of slow progress, therapeutic vaccines that direct the immune system to attack tumours could soon become a fixture of cancer treatment.
- Liam Drew
-
Article |
TRBC1-targeting antibody–drug conjugates for the treatment of T cell cancers
Anti-TRBC1 antibody–drug conjugates may offer a more potent T cell cancer therapy by bypassing the fratricide that may be limiting the efficacy of anti-TRBC1 CAR T cells in the clinical trial for patients with T cell cancers.
- Tushar D. Nichakawade
- , Jiaxin Ge
- & Suman Paul
-
News |
How to make an old immune system young again
Antibodies that target blood stem cells can rejuvenate immune responses in mice.
- Heidi Ledford
-
Article |
Targeting DCAF5 suppresses SMARCB1-mutant cancer by stabilizing SWI/SNF
DCAF5 has a quality-control function for SWI/SNF complexes and promotes the degradation of incompletely assembled SWI/SNF complexes in the absence of SMARCB1.
- Sandi Radko-Juettner
- , Hong Yue
- & Charles W. M. Roberts
-
News |
Cutting-edge CAR-T cancer therapy is now made in India — at one-tenth the cost
The treatment, called NexCAR19, raises hopes that this transformative class of medicine will become more readily available in low- and middle-income countries.
- Smriti Mallapaty
-
Career Q&A |
‘Woah, this is affecting me’: why I’m fighting racial inequality in prostate-cancer research
Olugbenga Samuel Oyeniyi sought a career with a stronger public-health focus after learning that Black men are twice as likely as white men to get prostate cancer.
- Jacqui Thornton
-
News & Views |
Whittling down the bacterial subspecies that might drive colon cancer
Understanding the factors that drive formation of particular types of cancer can aid efforts to develop better diagnostics or treatments. The identification of a bacterial subspecies with a connection to colon cancer has clinical relevance.
- Cynthia L. Sears
- & Jessica Queen
-
Article
| Open AccessTranscription–replication conflicts underlie sensitivity to PARP inhibitors
Poly(ADP-ribose) polymerase 1 (PARP1) functions together with TIMELESS and TIPIN to protect the replisome in early S phase from transcription–replication conflicts, and inhibiting PARP1 enzymatic activity may suffice for treatment efficacy in homologous recombination-deficient settings.
- Michalis Petropoulos
- , Angeliki Karamichali
- & Thanos D. Halazonetis
-
Article
| Open AccessA distinct Fusobacterium nucleatum clade dominates the colorectal cancer niche
A study reveals that Fusobacterium nucleatum subspecies animalis is bifurcated into two distinct clades, and shows that only one of these dominates the colorectal cancer niche, probably through increased colonization of the human gastrointestinal tract.
- Martha Zepeda-Rivera
- , Samuel S. Minot
- & Christopher D. Johnston
-
Article
| Open AccessEvolutionary trajectories of small cell lung cancer under therapy
We uncover key processes of the genomic evolution of small cell lung cancer under therapy, identify the common ancestor as the source of clonal diversity at relapse and show central genomic patterns associated with drug response.
- Julie George
- , Lukas Maas
- & Roman K. Thomas
-
Obituary |
Anthony Epstein (1921–2024), discoverer of virus causing cancer in humans
Pathologist whose finding that viruses can trigger tumours in humans transformed medical research.
- Alan Rickinson
Browse broader subjects
Browse narrower subjects
- Bone cancer
- Breast cancer
- Cancer epidemiology
- Cancer genetics
- Cancer genomics
- Cancer imaging
- Cancer metabolism
- Cancer microenvironment
- Cancer models
- Cancer of unknown primary
- Cancer prevention
- Cancer screening
- Cancer stem cells
- Cancer therapy
- CNS cancer
- Cysts
- Embryonal neoplasms
- Endocrine cancer
- Eye cancer
- Gastrointestinal cancer
- Germ cell tumours
- Gynaecological cancer
- Haematological cancer
- Hamartoma
- Head and neck cancer
- Lung cancer
- Mesothelioma
- Metastasis
- Oncogenes
- Oral cancer
- Paediatric cancer
- Sarcoma
- Skin cancer
- Testicular cancer
- Tumour angiogenesis
- Tumour biomarkers
- Tumour heterogeneity
- Tumour immunology
- Tumour-suppressor proteins
- Tumour virus infections
- Urological cancer